ANTI-EGFR OR ANTI-VEGF IN FIRST-LINE RAS WILD-TYPE METASTASTIC CRC PATIENTS: CAN WE DEFINE AN "OPTIM...

Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population

S. Stintzing